FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2637-2639 December 22, 2005 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Eleven years after the first long-acting beta-agonist, salmeterol, was approved for sale in the United States, the Food and Drug Administration (FDA) has issued a stern public health advisory alerting "health care professionals and patients that these medicines may increase the chance of severe asthma episodes, and death when those episodes occur" (www.fda.gov/cder/drug/advisory/LABA.htm). The announcement followed a July 2005 meeting of an FDA advisory committee on this topic. What are the consequences of this advisory for the treatment of asthma?

Currently, inhaled corticosteroids are the most effective treatment for the symptoms of persistent asthma. However, in patients with . . . [Full Text of this Article]

Source Information

Dr. Martinez is a professor of pediatrics and director of the Arizona Respiratory Center, University of Arizona College of Medicine, Tucson.

Related Letters:

Safety of Long-Acting Beta-Agonists
Mintz M. L., O'Connor G. T., Martinez F. D.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1206-1208, Mar 16, 2006. Correspondence

This article has been cited by other articles:

• Wijesinghe, M., Weatherall, M., Perrin, K., Harwood, M., Beasley, R. (2009). Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J 34: 803-811 [Abstract] [Full Text]  
• Kramer, J. M. (2009). Balancing the Benefits and Risks of Inhaled Long-Acting Beta-Agonists -- The Influence of Values. NEJM 360: 1592-1595 [Full Text]  
• Drazen, J. M., O'Byrne, P. M. (2009). Risks of Long-Acting Beta-Agonists in Achieving Asthma Control. NEJM 360: 1671-1672 [Full Text]  
• Wijesinghe, M., Weatherall, M., Perrin, K., Crane, J., Beasley, R. (2009). International Trends in Asthma Mortality Rates in the 5- to 34-Year Age Group: A Call for Closer Surveillance. Chest 135: 1045-1049 [Abstract] [Full Text]  
• Martinez, F. D. (2009). Managing Childhood Asthma: Challenge of Preventing Exacerbations. Pediatrics 123: S146-S150 [Abstract] [Full Text]  
• Beasley, R., Martinez, F. D., Hackshaw, A., Rabe, K. F., Sterk, P. J., Djukanovic, R. (2009). Safety of long-acting {beta}-agonists: urgent need to clear the air remains. Eur Respir J 33: 3-5 [Full Text]  
• Jaeschke, R., O'Byrne, P. M., Mejza, F., Nair, P., Lesniak, W., Brozek, J., Thabane, L., Cheng, J., Schunemann, H. J., Sears, M. R., Guyatt, G. (2008). The Safety of Long-Acting {beta}-Agonists among Patients with Asthma Using Inhaled Corticosteroids: Systematic Review and Metaanalysis. Am. J. Respir. Crit. Care Med. 178: 1009-1016 [Abstract] [Full Text]  
• LANG, D. M. (2008). New asthma guidelines emphasize control, regular monitoring. Cleveland Clinic Journal of Medicine 75: 641-653 [Abstract] [Full Text]  
• Wijesinghe, M, Perrin, K, Harwood, M, Weatherall, M, Beasley, R (2008). The risk of asthma mortality with inhaled long acting {beta}-agonists. Postgrad. Med. J. 84: 467-472 [Abstract] [Full Text]  
• Cazzola, M., Matera, M. G. (2007). Review: Safety of long-acting {beta}2 -agonists in the treatment of asthma. Ther Adv Respir Dis 1: 35-46 [Abstract]  
• Townshend, J, Hails, S, Mckean, M (2007). Management of asthma in children. BMJ 335: 253-257 [Full Text]  
• The American Lung Association Asthma Clinical Rese, (2007). Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma. NEJM 356: 2027-2039 [Abstract] [Full Text]  
• Wechsler, M. E., Shepard, J.-A. O., Mark, E. J. (2007). Case 15-2007 -- A 20-Year-Old Woman with Asthma and Cardiorespiratory Arrest. NEJM 356: 2083-2091 [Full Text]  
• Barnes, N. (2007). Spoilt for Choice?. Am. J. Respir. Crit. Care Med. 175: 208-209 [Full Text]  
• Deykin, A., Wechsler, M. E., Boushey, H. A., Chinchilli, V. M., Kunselman, S. J., Craig, T. J., DiMango, E., Fahy, J. V., Kraft, M., Leone, F., Lazarus, S. C., Lemanske, R. F. Jr., Martin, R. J., Pesola, G. R., Peters, S. P., Sorkness, C. A., Szefler, S. J., Israel, E., for the National Heart, Lung, and Blood Institute', (2007). Combination Therapy with a Long-Acting beta-Agonist and a Leukotriene Antagonist in Moderate Asthma. Am. J. Respir. Crit. Care Med. 175: 228-234 [Abstract] [Full Text]  
• The American Lung Association Asthma Clinical Rese, (2007). Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma. Am. J. Respir. Crit. Care Med. 175: 235-242 [Abstract] [Full Text]  
• Ernst, P., McIvor, A., Ducharme, F. M., Boulet, L.-P., FitzGerald, M., Chapman, K. R., Bai, T., for the Canadian Asthma Guideline Group, (2006). Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids.. ANN INTERN MED 145: 692-694 [Abstract] [Full Text]  
• Weinberger, M., Abu-Hasan, M. (2006). Life-Threatening Asthma during Treatment with Salmeterol. NEJM 355: 852-853 [Full Text]  
• Boswell-Smith, V., Spina, D., Oxford, A. W., Comer, M. B., Seeds, E. A., Page, C. P. (2006). The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J. Pharmacol. Exp. Ther. 318: 840-848 [Abstract] [Full Text]  
• Mintz, M. L., O'Connor, G. T., Martinez, F. D. (2006). Safety of long-acting beta-agonists.. NEJM 354: 1206-1208 [Full Text]